Scientific publications
- [HEMATO-ONCOLOGY]
- [TRANSLATIONAL IMMUNOMICS IN HEMATOLOGICAL NEOPLASMS]
- [COMPUTATIONAL BIOLOGY AND TRANSLATIONAL GENOMICS]
- [THERAPEUTIC INNOVATION]
- [MEDICINAL CHEMISTRY]
- [BIOINFORMATICS]
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity
Carmen Vicente, Elena Arriazu, Elena Martínez-Balsalobre, Irene Peris, Nerea Marcotegui, Patricia García-Ramírez, Raffaella Pippa, Obdulia Rabal, Julen Oyarzábal, Elizabeth Guruceaga, Felipe Prósper, María C Mateos, María L Cayuela, María D Odero
Abstract
Acute myeloid leukemia (AML) is an aggressive disease associated with very poor prognosis. Most patients are older than 60 years, and in this group only 5-15% of cases survive over 5 years. Therefore, it is urgent to develop more effective targeted therapies. Inactivation of protein phosphatase 2 A (PP2A) is a recurrent event in AML, and overexpression of its endogenous inhibitor SET is detected in ~30% of patients. The PP2A activating drug FTY720 has potent anti-leukemic effects; nevertheless, FTY720 induces cardiotoxicity at the anti-neoplastic dose. Here, we have developed a series of non-phosphorylable FTY720 analogues as a new therapeutic strategy for AML.
Our results show that the lead compound CM-1231 re-activates PP2A by targeting SET-PP2A interaction, inhibiting cell proliferation and promoting apoptosis in AML cell lines and primary patient samples. Notably, CM-1231 did not induce cardiac toxicity, unlike FTY720, in zebrafish models, and reduced the invasion and aggressiveness of AML cells more than FTY720 in zebrafish xenograft models. In conclusion, CM-1231 is safer and more effective than FTY720; therefore, this compound could represent a novel and promising approach for treating AML patients with SET overexpression.
CITA DEL ARTÍCULO Cancer Lett. 2020 Jan 1;468:1-13. doi: 10.1016/j.canlet.2019.10.007.
![](/.resources/ModuloCUN/resources/img/publicaciones/icono-destacado-investigadores.png)
Our authors
![Carmen Vicente Vázquez. Programa Hemato-oncología Investigadora adscrita al proyecto del Grupo de Patología Mieloide del Cima Universidad de Navarra](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/hemato-oncologia/carmen-vicente-vazquez/jcr:content/carmen-vicente-vazquez.jpg)
![Elena Arriazu Ruiz. Programa Hemato-oncología Colaboradora de investigación del Grupo de Patología Mieloide del Cima Universidad de Navarra](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/hemato-oncologia/elena-arriazu-ruiz/jcr:content/elena-arriazu-ruiz.jpg)
![Nerea Marcotegui. Programa Hemato-Oncología. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/hemato-oncologia/nerea-marcotegui-arza/jcr:content/nerea-marcotegui-arza.jpg)
![Elisabet Guruceaga. Programa Biología Computacional. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-transversales/biologia-computacional/elisabet-guruceaga-martinez/jcr:content/elisabet-guruceaga-martinez.jpg)